BlackBerry Downgraded on High P/E; 4basebio Hires mRNA Expert Coller
BB•Barclays downgraded BlackBerry to Reduce after shares surged 200% in two months, noting a forward P/E of 67.21 and P/S of 10.12. 4basebio appointed Dr Jeff Coller to its Strategic Advisory Board to advance scalable manufacturing of next-generation nucleic acid therapeutics.
1. Barclays Downgrades BlackBerry
Barclays cut its rating on BlackBerry to Reduce after shares climbed over 200% in two months. The firm flagged extreme overbought conditions and high forward valuation metrics as reasons for the downgrade.
2. BlackBerry's Valuation Metrics
BlackBerry now trades at a forward P/E ratio of 67.21 and a forward P/S ratio of 10.12, well above peers. Elevated multiples have raised concerns that current price levels may not be sustainable without stronger revenue growth.
3. QNX Revenue Growth Forecast
Management forecasts 15% growth in QNX software revenue to roughly $300 million in fiscal 2027. This segment serves automotive, robotics, and medical industries and is central to BlackBerry’s turnaround strategy.
4. 4basebio Appoints Dr Jeff Coller
4basebio added Dr Jeff Coller to its Strategic Advisory Board to leverage his mRNA biology expertise. His appointment aims to enhance the company’s capabilities in scalable DNA manufacturing for advanced genomic medicines.
